View Archive »
About The Cover
The cover for issue 64 of Oncotarget features Figure 2, "Principal component analysis based on gene expression," by Forster, et al.
|
|
Table of Contents
Editorial
|
| Prophylactic cranial irradiation PCI in locally advanced nonsmall cell lung cancer: time for hope |
|
https://doi.org/10.18632/oncotarget.25866
|
| 32274-32275 |
|
| Disabling an oncogenic transcription factor by targeting of control kinases |
|
https://doi.org/10.18632/oncotarget.25971
|
| 32276-32277 |
|
| A metabolic vulnerability of smallcell lung cancer |
|
https://doi.org/10.18632/oncotarget.25964
|
| 32278-32279 |
Research Papers
|
| xCT inhibition sensitizes tumors to γradiation via glutathione reduction |
|
https://doi.org/10.18632/oncotarget.25794
|
| 32280-32297 |
|
| Immune checkpoint inhibitor rechallenge in patients with advanced nonsmall cell lung cancer |
|
https://doi.org/10.18632/oncotarget.25949
|
| 32298-32304 |
|
| Terpenes from essential oils and hydrolate of Teucrium alopecurus triggered apoptotic events dependent on caspases activation and PARP cleavage in human colon cancer cells through decreased protein expressions |
|
https://doi.org/10.18632/oncotarget.25955
|
| 32305-32320 |
|
| Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer |
|
https://doi.org/10.18632/oncotarget.25962
|
| 32321-32330 |
|
| Snail mediates repression of the Dlk1Dio3 locus in lung tumorinfiltrating immune cells |
|
https://doi.org/10.18632/oncotarget.25965
|
| 32331-32345 |
|
| Online structurebased screening of purchasable approved drugs and natural compounds: retrospective examples of drug repositioning on cancer targets |
|
https://doi.org/10.18632/oncotarget.25966
|
| 32346-32361 |
|
| RNA based individualized drug selection in breast cancer patients without patientmatched normal tissue |
|
https://doi.org/10.18632/oncotarget.25981
|
| 32362-32372 |
|
| Association between red and processed meat intake and colorectal adenoma incidence and recurrence: a systematic review and metaanalysis |
|
https://doi.org/10.18632/oncotarget.23561
|
| 32373-32382 |
Reviews
|
| Spanish Lymphoma Group GELTAMO guidelines for the diagnosis staging treatment and followup of diffuse large Bcell lymphoma |
|
https://doi.org/10.18632/oncotarget.25892
|
| 32383-32399 |
Errata
|
| Erratum: Will PI3K pathway inhibitors be effective as single agents in patients with cancer |
|
https://doi.org/10.18632/oncotarget.26017
|
| 32400-32400 |
Corrections
|
| Correction: Antigenspecific T cell Redirectors: a nanoparticle based approach for redirecting T cells |
|
https://doi.org/10.18632/oncotarget.26018
|
| 32401-32401 |
|
| Correction: Systematic discovery of drug action mechanisms by an integrated chemical genomics approach: identification of functional disparities between azacytidine and decitabine |
|
https://doi.org/10.18632/oncotarget.26019
|
| 32402-32402 |
|
| Correction: Loss of EGFR signalingregulated miR203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance |
|
https://doi.org/10.18632/oncotarget.26020
|
| 32403-32403 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
